The findings from Alnylam’s highly anticipated readout  

Off Biotech, biotechnology, Business, cancer, drug development, drug prices, drug pricing, FDA, finance, genetics, Health, Human Health, Life Sciences, Medicine, Pharma, Pharmaceuticals, policy, Politics, research, Science and Research, The Readout, White House

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

On top of today’s Alnylam news, we have Congress gearing up to vote on Medicare coverage for multi-cancer screenings and obesity drug coverage. Also, updates on Vertex’s type 1 diabetes cell therapy, and a push for phage therapy.

Read the rest…

Read Original Article: The findings from Alnylam’s highly anticipated readout   »

About The Author